Vinacomin - Machinery JSC (HNX:CTT)

Ligand Pharmaceuticals Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,277,064	2,292,681	2,276,830	2,260,244	2,069,284	1,492,249
Revenue Growth (YoY)	-2.37%	0.70%	0.73%	9.23%	38.67%	-0.57%
Cost of Revenue	2,113,563	2,130,716	2,156,333	2,135,205	1,958,027	1,386,855
Gross Profit	163,500	161,965	120,498	125,038	111,257	105,394
Selling, General & Admin	138,405	136,710	92,753	96,116	84,339	79,542
Operating Expenses	138,405	136,710	92,753	96,116	84,339	79,542
Operating Income	25,096	25,255	27,745	28,923	26,918	25,852
Interest Expense	-2,712	-5,146	-13,005	-13,107	-14,438	-14,114
Interest & Investment Income	19.22	19.22	7.74	199.88	5.14	20.47
Currency Exchange Gain (Loss)	214.98	214.98	113.2	-	-	-
Other Non Operating Income (Expenses)	-796.6	-1.29	467.41	-2,196	80	384.11
EBT Excluding Unusual Items	21,821	20,342	15,328	13,819	12,565	12,143
Other Unusual Items	-3,267	-3,267	-	-	-	-
Pretax Income	18,554	17,075	15,328	13,819	12,565	12,143
Income Tax Expense	4,064	3,765	3,277	2,987	2,543	2,444
Net Income	14,490	13,310	12,051	10,833	10,022	9,699
Net Income to Common	14,490	13,310	12,051	10,833	10,022	9,699
Net Income Growth	12.68%	10.44%	11.25%	8.09%	3.32%	38.32%
Shares Outstanding (Basic)	5	5	5	5	5	5
Shares Outstanding (Diluted)	5	5	5	5	5	5
Shares Change (YoY)	-99.78%	-	-11.73%	13.29%	-0.02%	0.01%
EPS (Basic)	2812.68	2834.00	2566.00	2036.00	2134.00	2065.00
EPS (Diluted)	2812.68	2834.00	2566.00	2036.00	2134.00	2065.00
EPS Growth	51304.14%	10.44%	26.03%	-4.59%	3.34%	38.31%
Free Cash Flow	110,711	59,402	129,734	-1,603	18,468	-9,790
Free Cash Flow Per Share	21489.87	12647.94	27623.02	-301.28	3932.55	-2084.23
Dividend Per Share	-	-	-	1300.000	1300.000	-
Gross Margin	7.18%	7.06%	5.29%	5.53%	5.38%	7.06%
Operating Margin	1.10%	1.10%	1.22%	1.28%	1.30%	1.73%
Profit Margin	0.64%	0.58%	0.53%	0.48%	0.48%	0.65%
Free Cash Flow Margin	4.86%	2.59%	5.70%	-0.07%	0.89%	-0.66%
EBITDA	72,480	64,295	57,414	59,404	54,701	56,878
EBITDA Margin	3.18%	2.80%	2.52%	2.63%	2.64%	3.81%
D&A For EBITDA	47,385	39,040	29,669	30,482	27,783	31,026
EBIT	25,096	25,255	27,745	28,923	26,918	25,852
EBIT Margin	1.10%	1.10%	1.22%	1.28%	1.30%	1.73%
Effective Tax Rate	21.90%	22.05%	21.38%	21.61%	20.24%	20.13%
Revenue as Reported	2,277,064	2,292,681	2,276,830	2,260,244	2,069,284	1,492,249

Source: S&P Global Market Intelligence. Standard template. Financial Sources.